Lisa Nolan Joins Rexahn Pharmaceuticals
Executive Summary
Cancer focused Rexahn Pharmaceuticals Inc. has appointed Lisa Nolan to the newly created position of chief business officer (CBO). She previously held similar positions at Relmada Therapeutics and Topigen Pharmaceuticals, where she was CBO, and SkyePharma, where she was vice president, global business development and strategic marketing. Nolan has also been managing director of Nolex Advisors LLC.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Pipeline Watch: 16 Approvals And 21 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: New Hires At Everest Medicines, Arvinas, Fulcrum Therapeutics And More
Recent executive changes in the industry include seven new chief medical officers, and new chief commercial officers at Adaptimmune Therapeutics and Syndax Pharmaceuticals.